<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David T Rubin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nathaniel Aviv Cohen, MBBCh
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sunanda V Kane, MD, MSPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The thiopurines (ie,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [AZA] and mercaptopurine, also known as
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         [6-MP]) exert a glucocorticoid-sparing effect for patients with inflammatory bowel disease (IBD) who cannot maintain remission when glucocorticoids are tapered or withdrawn. Nonetheless, drug-related adverse events such as bone marrow suppression and hepatotoxicity may limit thiopurine use. Strategies for reducing the risk of adverse events, improving tolerability, and improving disease control include pretreatment screening for thiopurine methyltransferase (TPMT) enzyme activity, routine laboratory monitoring, and therapeutic drug monitoring [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will review pretreatment evaluation and approach to therapeutic drug monitoring for patients with IBD on thiopurine therapy. The discussion is generally consistent with the American Gastroenterological Association (AGA) guideline on therapeutic drug monitoring for patients with IBD [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The pharmacology and empiric dosing of thiopurines for patients with IBD are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         Medical management of Crohn disease (CD) and ulcerative colitis is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">
          "Overview of the medical management of mild (low risk) Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">
          "Medical management of low-risk adult patients with mild to moderate ulcerative colitis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2605526310">
         <span class="h1">
          DRUG METABOLISM
         </span>
        </p>
        <p class="headingAnchor" id="H3755142888">
         <span class="h2">
          Thiopurine metabolites
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thiopurines that are typically used for treating IBD include
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA) and
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         (6-MP). AZA is a prodrug that is metabolized to 6-MP, which is then further metabolized along an anabolic pathway to several metabolites including 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP). Thiopurine methyltransferase (TPMT) is one of the key enzymes in thiopurine metabolism  (
         <a class="graphic graphic_figure graphicRef72170" href="/z/d/graphic/72170.html" rel="external">
          figure 1
         </a>
         ). Patients with low or absent TPMT enzyme activity can develop bone marrow toxicity with thiopurine therapy due to excess production of 6-TG metabolites, while elevated 6-MMP levels have been associated with hepatotoxicity [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1897922383">
         <span class="h2">
          Genetic factors affecting drug metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic polymorphisms of the
         <em>
          TPMT
         </em>
         gene can result in functional inactivation or markedly decreased activity of the enzyme and an increased risk of treatment-related leukopenia [
         <a href="#rid4">
          4-7
         </a>
         ]. Approximately 10 percent of the general population have reduced TPMT activity and 0.3 percent (1 in 300) of the population have very low or absent activity [
         <a href="#rid8">
          8
         </a>
         ]. TPMT enzyme activity is a major factor determining thiopurine metabolism, and thus, it affects 6-TG and 6-MMP levels  (
         <a class="graphic graphic_figure graphicRef72170" href="/z/d/graphic/72170.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Pretreatment determination of
         <em>
          TPMT
         </em>
         genotype to guide dosing has been shown to be effective at reducing the risk of thiopurine-related bone marrow suppression (most frequently leukopenia) [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia"
         </a>
         .)
        </p>
        <p>
         Variants in another metabolizing enzyme, NUDT15 (nucleoside diphosphate-linked moiety X motif 15, NUDIX 15), have been identified that strongly influence thiopurine tolerance in patients with IBD [
         <a href="#rid10">
          10
         </a>
         ]. The NUDT15 poor metabolizer phenotype has been observed primarily in Asian populations (up to 29 percent of individuals), but it is also common in Hispanic populations (21 percent) and, to a lesser degree, in European populations (3 percent) [
         <a href="#rid11">
          11-14
         </a>
         ]. Homozygous carriers of NUDT15 variants are extremely intolerant of thiopurine compounds because of risk of bone marrow suppression. (See
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'
         </a>
         .)
        </p>
        <p>
         Data on other genetic polymorphisms are emerging and may provide further insight for individualizing dosing regimens for patients on thiopurine therapy [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2535447904">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1327472805">
         <span class="h2">
          Assessing TPMT enzyme activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with IBD who are evaluated for treatment with a thiopurine (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [AZA],
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         [6-MP]), we assess thiopurine methyltransferase (TPMT) enzyme activity with phenotype testing before starting therapy, and this approach is consistent with society guidelines [
         <a href="#rid2">
          2,17
         </a>
         ]. TPMT activity can be assessed by directly measuring enzyme activity in erythrocytes (phenotyping) or by genotype testing. The choice of testing varies by clinician preference, local laboratory availability, and cost. Of note, TPMT phenotype testing is generally preferred because the
         <em>
          TPMT
         </em>
         gene is highly polymorphic, and genotypic testing may misclassify some patients [
         <a href="#rid18">
          18
         </a>
         ]. In addition, TPMT phenotype testing is typically a less costly option.
        </p>
        <p>
         TPMT phenotype or genotype testing is suggested but not required by the US Food and Drug Administration (FDA) prior to thiopurine use.
        </p>
        <p>
         It is important to recognize that patients with normal TPMT activity can develop bone marrow and/or liver toxicity in a dose-related fashion; thus, routine laboratory monitoring is required for all patients [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="local">
          'Routine laboratory monitoring'
         </a>
         below.)
        </p>
        <p>
         In the United States, testing for TPMT enzyme activity (phenotyping) is more commonly available and used in clinical practice, while
         <em>
          TPMT
         </em>
         genotypes have been correlated with TPMT activity (see
         <a class="local">
          'Therapeutic drug monitoring'
         </a>
         below) [
         <a href="#rid3">
          3,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal TPMT activity – The majority of the general population have the most common TPMT alleles (wild type), and this genotype has been associated with normal enzyme activity (12 to 15 units/mL). For patients with normal enzyme activity, we typically begin a low dose thiopurine (eg, 6-MP 25 mg daily) and gradually increase the dose to a target, weight-based dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative approach that is preferred by some clinicians is to initiate AZA or 6-MP at the target, weight-based dose (maximum dose: AZA 2.5 mg/kg daily or 6-MP 1.5 mg/kg daily) rather than starting low dose AZA or 6-MP and gradually increasing the dose until the target dose is achieved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some patients have above normal TPMT activity (&gt;15 units/mL), which has been associated with lower rates of clinical remission [
         <a href="#rid21">
          21
         </a>
         ]. For such patients, the approach to monitoring and dose adjustments is unchanged (ie based on 6-thioguanine (6-TG) levels and routine laboratory studies).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate TPMT activity – Approximately 10 percent of the general population is heterozygous for a variant TPMT allele and has intermediate enzyme activity (5 to 12 units/mL). For patients with intermediate enzyme activity, we begin a low dose thiopurine (eg, 6-MP 25 mg daily) and gradually increase the dose to a target weight-based dose. Dose escalation is based on 6-TG levels (obtained every four weeks) and other laboratory parameters (eg, white blood cell count, obtained two weeks after any dose increase).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low or absent TPMT activity – Approximately 0.3 percent (1 in 300) of the general population is homozygous for TPMT variants and thus have low or absent activity (&lt;5 unit/mL). The lack of enzyme activity causes thiopurines to be preferentially metabolized to produce high levels of 6-TG, which then leads to bone marrow toxicity and leukopenia. We do not use thiopurines for patients who have low or absent enzyme activity (or are homozygous for TPMT variants) to avoid risk of potentially life-threatening toxicity [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Dosing for AZA and 6-MP, including dose adjustments based on routine laboratory monitoring (eg, complete blood count [CBC]), is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dosing and monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H206071185">
         <span class="h2">
          Evaluating for drug-drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coexisting medications can affect thiopurine metabolism. As an example,
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         can reversibly inhibit TPMT activity and thus lead to corresponding increases in 6-TG levels with resultant leukopenia [
         <a href="#rid23">
          23-25
         </a>
         ]. However, patients on mesalamine and a thiopurine do not require more frequent laboratory monitoring. (See
         <a class="local">
          'Routine laboratory monitoring'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          Allopurinol
         </a>
         inhibits the enzyme xanthine oxidase and should be avoided, since concomitant use of allopurinol and a thiopurine can potentially lead to life-threatening bone marrow suppression. However, for patients with thiopurine resistance, investigational use of allopurinol has been reported. (See
         <a class="local">
          'Patients with thiopurine resistance'
         </a>
         below.)
        </p>
        <p>
         For more detailed information on potential drug-drug interactions, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         within UpToDate. Such
         <a class="external" href="/drug-interactions">
          drug interaction program
         </a>
         s are meant to be a general guide, and consultation with a clinical pharmacist may provide more specific insight.
        </p>
        <p class="headingAnchor" id="H504016694">
         <span class="h2">
          Is there a role for assessing other polymorphisms?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recognition of
         <em>
          NUDT15
         </em>
         as an additional genetic polymorphism affecting thiopurine metabolism has added to our understanding of clinical response to thiopurine therapy and risk of drug toxicity. Although consensus guidelines regarding testing for
         <em>
          NUDT15
         </em>
         polymorphisms are lacking, we test patients who are at higher risk for this polymorphism (eg, Asian individuals, Hispanic individuals). Similar to TPMT testing,
         <em>
          NUDT15
         </em>
         genotypes correlate with metabolic activity that is classified as normal, intermediate, or poor/limited. We adjust thiopurine dosing with an approach that is similar to dose adjustments related to TPMT activity [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Assessing TPMT enzyme activity'
         </a>
         above.)
        </p>
        <p>
         We do not routinely test for
         <em>
          NUDT15
         </em>
         polymorphisms in other populations because data to support such testing are limited. (See
         <a class="local">
          'Drug metabolism'
         </a>
         above.)
        </p>
        <p>
         For patients with normal TPMT activity who unexpectedly develop leukopenia when a thiopurine is initiated, a polymorphism such as
         <em>
          NUDT15
         </em>
         may be suspected, and some clinicians perform
         <em>
          NUDT15
         </em>
         genotyping in this setting. Screening for genetic factors that influence drug metabolism is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1994681977">
         <span class="h1">
          ROUTINE LABORATORY MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who begin thiopurine therapy, laboratory testing (ie, complete blood count [CBC], serum aminotransferases, total bilirubin, and amylase) is typically performed weekly for the first four weeks, then every two weeks for weeks five through 12, and at least every three months thereafter. In addition, laboratory testing is performed in two weeks following dose escalation. Laboratory monitoring and dose adjustment for patients with cytopenia (eg, leukopenia, thrombocytopenia) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dosing and monitoring'
         </a>
         .)
        </p>
        <p>
         Long-term, routine laboratory monitoring is an essential aspect of care because patients with normal TPMT activity can develop bone marrow suppression and/or liver toxicity at any time during treatment [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1783998803">
         <span class="h1">
          THERAPEUTIC DRUG MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H3080381629">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic drug monitoring uses sampling of plasma or serum drug levels to determine optimal drug dosing. This technique has been applied to several therapeutic areas including antibiotics and immunosuppressive drugs such as anti-tumor necrosis factor (TNF) agents. (See
         <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">
          "Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Monitoring'
         </a>
         .)
        </p>
        <p>
         For patients with IBD, therapeutic drug monitoring is one of several methods that are used for assessing clinical response. Other important methods include monitoring symptoms, evaluating endoscopic appearance and histology, and routine laboratory monitoring. For example, some adverse reactions (such as pancreatitis) can occur unrelated to elevated 6-thioguanine (6-TG) or 6-methylmercaptopurine (6-MMP) levels [
         <a href="#rid27">
          27
         </a>
         ]. Thus, measuring metabolite levels does not replace other monitoring techniques including routine, long-term laboratory monitoring. In addition, therapeutic drug monitoring with metabolite testing may not be available in some clinical laboratories. (See
         <a class="local">
          'Routine laboratory monitoring'
         </a>
         above.)
        </p>
        <p>
         For patients with IBD, thiopurine metabolite monitoring (ie 6-TG and 6-MMP) may be used for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with active disease despite thiopurine therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with adverse effects (eg, leukopenia) that are possibly due to thiopurine therapy
        </p>
        <p>
        </p>
        <p>
         Therapeutic drug monitoring in the setting of suboptimal disease control is referred to as reactive testing or monitoring [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1971864413">
         <span class="h2">
          Drug adjustments based on metabolite levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with active IBD despite thiopurine therapy, studies have suggested that certain 6-TG levels correlate with therapeutic efficacy and bone marrow toxicity, while markedly elevated 6-MMP levels correlate with hepatotoxicity [
         <a href="#rid27">
          27-36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6-TG level &lt;230 picomoles/8 X 10
         </strong>
         <strong>
          <sup>
           8
          </sup>
         </strong>
         <strong>
          erythrocytes
         </strong>
         – Low or absent 6-TG levels are suggestive of noncompliance, suboptimal thiopurine dosing, or preferential metabolism to 6-MMP instead of 6-TG [
         <a href="#rid33">
          33,37
         </a>
         ]. For patients with low or absent 6-TG levels, we confirm that the patient is compliant and that 6-MMP levels and complete blood count (CBC) are normal. For such patients, we increase the thiopurine dose. Routine laboratory monitoring is performed with every dose increase and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dosing and monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6-TG level between 230 and 450 picomoles/8 X 10
         </strong>
         <strong>
          <sup>
           8
          </sup>
         </strong>
         <strong>
          erythrocytes
         </strong>
         – A commonly used target level for 6-TG is between 230 and 450 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes because this range has been associated with therapeutic efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6-TG level &gt;450 picomoles/8 X 10
         </strong>
         <strong>
          <sup>
           8
          </sup>
         </strong>
         <strong>
          erythrocytes
         </strong>
         – 6-TG levels &gt;450 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes have been associated with increased risk for developing bone marrow suppression [
         <a href="#rid38">
          38
         </a>
         ]. The management of patients with cytopenia in the setting of thiopurine use is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dose adjustment for cytopenia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6-MMP level &gt;5700 picomoles/8 X 10
         </strong>
         <strong>
          <sup>
           8
          </sup>
         </strong>
         <strong>
          erythrocytes
         </strong>
         – 6-MMP concentrations &gt;5700 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes have been associated with increased risk for developing hepatotoxicity [
         <a href="#rid29">
          29
         </a>
         ]. However, 6-MMP levels are not a highly accurate predictor of hepatotoxicity in all patients [
         <a href="#rid39">
          39
         </a>
         ]. Dose adjustment for patients with normal liver biochemical tests but with elevated 6-MMP levels includes administering the thiopurine in divided doses. Dividing the daily dose has been shown to decrease 6-MMP levels without affecting 6-TG levels, thus reducing the development of adverse effects without compromising clinical benefit [
         <a href="#rid40">
          40
         </a>
         ]. The rationale behind this method is that it reduces thiopurine methyltransferase (TPMT) induction during treatment, allowing more drug to be converted to 6-TG [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Dose-optimization or toxicity-avoidance strategies based upon drug metabolite monitoring have been associated with improved clinical outcomes. In an observational study of 63 patients with active IBD, using 6-TG and 6-MMP concentrations to guide treatment (eg, dose adjustment, switching to a different medication) was associated with higher rates of clinical response compared with no drug monitoring (86 versus 17 percent; risk ratio [RR] 5.15, CI 1.82-14.56) [
         <a href="#rid3">
          3,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H450820779">
         <span class="h2">
          Other factors affecting metabolite levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to genetic polymorphisms, other factors may affect 6-TG levels:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factors associated with subtherapeutic 6-TG levels – Obesity has been associated with lower 6-TG levels. As an example, in a study including 132 patients with IBD, body mass index ≥30 kg/m
         <sup>
          2
         </sup>
         was associated with higher rates of subtherapeutic 6-TG levels (ie &lt;230 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes) compared with normal body mass index (65 versus 35 percent) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factors associated with elevated 6-TG levels include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lifestyle factors – Tobacco use and chronic alcohol use have been identified as risk factors for elevated 6-TG levels [
         <a href="#rid43">
          43,44
         </a>
         ]. Chronic alcohol consumption, through the depletion of S-adenosylmethionine (which is essential for TPMT enzyme activity), may increase 6-TG levels and thus increase risk of bone marrow suppression [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coexisting medications – Higher levels of 6-TG have been reported in patients on other IBD medications such as
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Loop diuretics may have the potential to increase 6-TG levels by inhibiting TPMT enzyme activity [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Evaluating for drug-drug interactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Another limitation to measuring metabolite levels is that the available testing does not distinguish between the three phosphorylated forms of thiopurine metabolites. The most common phosphate form of thiopurine metabolites is 6-thioguanosine triphosphate (6-TGTP), which is responsible for most of the bioactivity. 6-TGTP levels &gt;100 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes have been associated with clinical response [
         <a href="#rid47">
          47
         </a>
         ]. Methods for detecting different metabolite forms are less accurate than conventional testing; however, more accurate methods of determining these levels may be available in the future.
        </p>
        <p class="headingAnchor" id="H30620787">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2187404539">
         <span class="h2">
          Patients with thiopurine resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who do not respond to initial dosing of thiopurines and/or to dose escalation are described as having thiopurine resistance [
         <a href="#rid37">
          37
         </a>
         ]. For such patients, dose escalation of either
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA) or
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         (6-MP) does not typically result in therapeutic 6-thioguanine (6-TG) levels, but rather leads to increased 6-methylmercaptopurine (6-MMP) levels and hepatoxicity.
        </p>
        <p>
         For patients with thiopurine resistance, an investigational approach has been to use
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         that results in shunting of 6-MMP metabolites with a subsequent shift in drug metabolism towards 6-TG [
         <a href="#rid48">
          48-50
         </a>
         ]. However, additional studies are needed to assess the efficacy and safety of this strategy before it can be used routinely in clinical practice. Because of the increased risk of bone marrow toxicity and leukopenia, the use of allopurinol for managing thiopurine resistance remains investigational.
        </p>
        <p class="headingAnchor" id="H423924393">
         <span class="h2">
          Patients treated with combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are initiating a thiopurine as part of combination therapy (eg, an anti-tumor necrosis factor [TNF] agent plus a thiopurine), we use the pretreatment testing and drug monitoring strategies as described above. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above and
         <a class="local">
          'Therapeutic drug monitoring'
         </a>
         above.)
        </p>
        <p>
         Preliminary data suggest that testing for selected genetic variants may help identify patients who are at increased risk for developing anti-drug antibodies with anti-TNF therapy and who may benefit from the addition of a thiopurine [
         <a href="#rid51">
          51
         </a>
         ]. The use of combination therapy for patients with IBD including pretreatment testing and drug monitoring with anti-TNF therapy is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults", section on 'Combination therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">
          "Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2111077948">
         <span class="h2">
          Asian populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data have suggested that Asian individuals required a lower thiopurine dose and were at higher risk for leukopenia [
         <a href="#rid52">
          52-54
         </a>
         ]. As an example, in a study including 252 Asian individuals with IBD, 6-TG levels of 180 to 355 picomoles/8 X 10
         <sup>
          8
         </sup>
         erythrocytes were associated with clinical remission, and this range is lower than the reference range used for the general population [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
         In addition, testing for TPMT activity prior to initiating thiopurine therapy may not be useful for Asian individuals because genetic polymorphisms in the TPMT enzyme are rare in such patients and testing for other polymorphisms such as
         <em>
          NUDT15
         </em>
         is more appropriate [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="local">
          'Is there a role for assessing other polymorphisms?'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3985327927">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109937.html" rel="external">
          "Society guideline links: Ulcerative colitis in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">
          "Society guideline links: Crohn disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – The thiopurines (ie,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [AZA] and
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         [6-MP]) exert a glucocorticoid-sparing effect for patients with inflammatory bowel disease (IBD) who cannot maintain remission when glucocorticoids are tapered or withdrawn. However, drug-related adverse events such as bone marrow suppression and hepatotoxicity may limit thiopurine use. Strategies for reducing the risk of adverse events and improving tolerability include pretreatment screening for thiopurine methyltransferase (TPMT) enzyme activity and routine laboratory and therapeutic drug monitoring during treatment. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug metabolism
         </strong>
         – TPMT enzyme activity is a major factor determining thiopurine metabolism, and thus, it affects metabolite levels (eg, 6-thioguanine [6-TG], 6-methylmercaptopurine [6-MMP])  (
         <a class="graphic graphic_figure graphicRef72170" href="/z/d/graphic/72170.html" rel="external">
          figure 1
         </a>
         ). Genetic polymorphisms of the
         <em>
          TPMT
         </em>
         gene can result in markedly decreased or absent activity of the enzyme and an increased risk of treatment-related leukopenia. Approximately 10 percent of the general population have reduced TPMT activity and 0.3 percent (1 in 300) have very low or absent activity. (See
         <a class="local">
          'Drug metabolism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – For patients with IBD who are evaluated for treatment with a thiopurine, we assess TPMT enzyme activity with phenotype testing before starting therapy. In selected patients (eg, Asian individuals, Hispanic individuals), we assess for
         <em>
          NUDT15
         </em>
         polymorphisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TPMT activity can be assessed by directly measuring enzyme activity in erythrocytes (phenotyping) (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with normal or intermediate enzyme activity, we begin a low dose thiopurine (eg, 6-MP 25 mg daily) and gradually increase the dose to a target, weight-based dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with very low or absent enzyme activity, we avoid thiopurines because of the risk of bone marrow toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine laboratory monitoring
         </strong>
         – Long-term, routine laboratory monitoring is an essential aspect of care because patients with normal TPMT activity can develop bone marrow suppression and/or liver toxicity at any time during treatment. For patients who begin thiopurine therapy, laboratory testing (ie, complete blood count [CBC], serum aminotransferases, total bilirubin, and amylase) is typically performed weekly for the first four weeks, then every two weeks for weeks five through 12, and at least every three months thereafter. In addition, laboratory testing is performed in two weeks following any dose escalation. (See
         <a class="local">
          'Routine laboratory monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic drug monitoring
         </strong>
         – For patients with IBD, thiopurine metabolite monitoring (ie 6-TG and 6-MMP) may be used for (see
         <a class="local">
          'General principles'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with active disease despite thiopurine therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with adverse effects (eg, leukopenia) that are possibly due to thiopurine therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with active IBD despite thiopurine therapy, certain 6-TG levels correlate with therapeutic efficacy (230 and 450 picomoles/8 X
         <sup>
         </sup>
         10
         <sup>
          8
         </sup>
         erythrocytes) or bone marrow toxicity (&gt;450 picomoles/8 X
         <sup>
         </sup>
         10
         <sup>
          8
         </sup>
         erythrocytes), while markedly elevated 6-MMP levels correlate with hepatotoxicity. In addition to monitoring routine laboratory values (eg, CBC) and symptoms, thiopurine metabolite levels can also be used to guide drug dose adjustments. (See
         <a class="local">
          'Drug adjustments based on metabolite levels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2535461959">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Richard P MacDermott, MD for his contributions as author to prior versions of this topic review.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McNeill RP, Barclay ML. Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pharmacol 2020; 55:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017; 153:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017; 153:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang JY, Park SJ, Jung ES, et al. Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18:2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014; 46:1017.
          </a>
         </li>
         <li class="breakAll">
          https://pharmgkb.org/page/nudt15RefMaterials (Accessed on April 17, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moriyama T, Nishii R, Lin TN, et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2017; 27:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker GJ, Harrison JW, Heap GA, et al. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA 2019; 321:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019; 105:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson AL, Daniel LL, Jackson E, et al. Race, Genotype, and Azathioprine Discontinuation : A Cohort Study. Ann Intern Med 2022; 175:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. J Crohns Colitis 2018; 12:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appell ML, Berg J, Duley J, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 2013; 23:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisbert JP, Niño P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006; 101:2769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005; 22:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102:2747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuffari C, Théorêt Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003; 36:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005; 21:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau AC, Paul S, Del Tedesco E, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis 2014; 20:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103:3115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007; 102:2488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012; 36:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyer N, Kröplin T, Fricke L, Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001; 57:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon SS, Asher R, Jackson R, et al. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. J Crohns Colitis 2015; 9:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arenas M, Simpson G, Lewis CM, et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 2005; 51:2371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996; 49:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neurath MF, Kiesslich R, Teichgräber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology 2020; 158:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng R, Guo J, Zhang SH, et al. Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease. J Gastroenterol Hepatol 2019; 34:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung ES, Choi KW, Kim SW, et al. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019; 34:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang JP, Guan YY, Wu JH, et al. Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups. Br J Clin Pharmacol 2004; 58:163.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4058 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33120169" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780013" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28774547" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15118980" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16181376" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16431304" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11304783" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873214" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31446180" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25108385" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25108385" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28445187" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27535533" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Analysis of protein-coding genetic variation in 60,706 humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30806694" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30447069" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35724382" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Race, Genotype, and Azathioprine Discontinuation : A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29293971" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23407052" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nomenclature for alleles of the thiopurine methyltransferase gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10833476" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690596" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10464128" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17026564" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856081" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16181300" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764493" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11683683" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8949645" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618398" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10734022" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698762" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702978" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247179" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330913" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11218242" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15801918" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24418904" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11910342" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19086961" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764490" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22784257" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11417444" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Human thiopurine S-methyltransferase activity in uremia and after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20812329" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25968584" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16306100" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17988235" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8866635" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234047" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16128682" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296529" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18521913" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31600487" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30175864" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30851117" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15255798" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
